Global KRAS Inhibitor Industry Growth and Trends Forecast to 2031

Summary

According to APO Research, The global KRAS Inhibitor market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for KRAS Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of KRAS Inhibitor include Novartis, Jemincare, Amgen, Mirati Therapeutics, Innovent Biologics, Incyte, Erasca, Cardiff Oncology and BridgeBio Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for KRAS Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding KRAS Inhibitor.

The KRAS Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global KRAS Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

KRAS Inhibitor Segment by Company

Novartis
Jemincare
Amgen
Mirati Therapeutics
Innovent Biologics
Incyte
Erasca
Cardiff Oncology
BridgeBio Pharma
Boehringer Ingelheim

KRAS Inhibitor Segment by Type

Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Others

KRAS Inhibitor Segment by Application

Clinic Laboratories
Hospitals
Cancer Diagnostic Centres
Others

KRAS Inhibitor Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KRAS Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of KRAS Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KRAS Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of KRAS Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview

1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global KRAS Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global KRAS Inhibitor Sales Estimates and Forecasts (2020-2031)
1.3 KRAS Inhibitor Market by Type
1.3.1 Lung Cancer
1.3.2 Colorectal Cancer
1.3.3 Pancreatic Cancer
1.3.4 Others
1.4 Global KRAS Inhibitor Market Size by Type
1.4.1 Global KRAS Inhibitor Market Size Overview by Type (2020-2031)
1.4.2 Global KRAS Inhibitor Historic Market Size Review by Type (2020-2025)
1.4.3 Global KRAS Inhibitor Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America KRAS Inhibitor Sales Breakdown by Type (2020-2025)
1.5.2 Europe KRAS Inhibitor Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific KRAS Inhibitor Sales Breakdown by Type (2020-2025)
1.5.4 South America KRAS Inhibitor Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa KRAS Inhibitor Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics

2.1 KRAS Inhibitor Industry Trends
2.2 KRAS Inhibitor Industry Drivers
2.3 KRAS Inhibitor Industry Opportunities and Challenges
2.4 KRAS Inhibitor Industry Restraints
3 Market Competitive Landscape by Company

3.1 Global Top Players by KRAS Inhibitor Revenue (2020-2025)
3.2 Global Top Players by KRAS Inhibitor Sales (2020-2025)
3.3 Global Top Players by KRAS Inhibitor Price (2020-2025)
3.4 Global KRAS Inhibitor Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global KRAS Inhibitor Major Company Production Sites & Headquarters
3.6 Global KRAS Inhibitor Company, Product Type & Application
3.7 Global KRAS Inhibitor Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global KRAS Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 KRAS Inhibitor Players Market Share by Revenue in 2024
3.8.3 2023 KRAS Inhibitor Tier 1, Tier 2, and Tier 3
4 KRAS Inhibitor Regional Status and Outlook

4.1 Global KRAS Inhibitor Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global KRAS Inhibitor Historic Market Size by Region
4.2.1 Global KRAS Inhibitor Sales in Volume by Region (2020-2025)
4.2.2 Global KRAS Inhibitor Sales in Value by Region (2020-2025)
4.2.3 Global KRAS Inhibitor Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global KRAS Inhibitor Forecasted Market Size by Region
4.3.1 Global KRAS Inhibitor Sales in Volume by Region (2026-2031)
4.3.2 Global KRAS Inhibitor Sales in Value by Region (2026-2031)
4.3.3 Global KRAS Inhibitor Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 KRAS Inhibitor by Application

5.1 KRAS Inhibitor Market by Application
5.1.1 Clinic Laboratories
5.1.2 Hospitals
5.1.3 Cancer Diagnostic Centres
5.1.4 Others
5.2 Global KRAS Inhibitor Market Size by Application
5.2.1 Global KRAS Inhibitor Market Size Overview by Application (2020-2031)
5.2.2 Global KRAS Inhibitor Historic Market Size Review by Application (2020-2025)
5.2.3 Global KRAS Inhibitor Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America KRAS Inhibitor Sales Breakdown by Application (2020-2025)
5.3.2 Europe KRAS Inhibitor Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific KRAS Inhibitor Sales Breakdown by Application (2020-2025)
5.3.4 South America KRAS Inhibitor Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa KRAS Inhibitor Sales Breakdown by Application (2020-2025)
6 Company Profiles

6.1 Novartis
6.1.1 Novartis Comapny Information
6.1.2 Novartis Business Overview
6.1.3 Novartis KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis KRAS Inhibitor Product Portfolio
6.1.5 Novartis Recent Developments
6.2 Jemincare
6.2.1 Jemincare Comapny Information
6.2.2 Jemincare Business Overview
6.2.3 Jemincare KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Jemincare KRAS Inhibitor Product Portfolio
6.2.5 Jemincare Recent Developments
6.3 Amgen
6.3.1 Amgen Comapny Information
6.3.2 Amgen Business Overview
6.3.3 Amgen KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Amgen KRAS Inhibitor Product Portfolio
6.3.5 Amgen Recent Developments
6.4 Mirati Therapeutics
6.4.1 Mirati Therapeutics Comapny Information
6.4.2 Mirati Therapeutics Business Overview
6.4.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Mirati Therapeutics KRAS Inhibitor Product Portfolio
6.4.5 Mirati Therapeutics Recent Developments
6.5 Innovent Biologics
6.5.1 Innovent Biologics Comapny Information
6.5.2 Innovent Biologics Business Overview
6.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Innovent Biologics KRAS Inhibitor Product Portfolio
6.5.5 Innovent Biologics Recent Developments
6.6 Incyte
6.6.1 Incyte Comapny Information
6.6.2 Incyte Business Overview
6.6.3 Incyte KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Incyte KRAS Inhibitor Product Portfolio
6.6.5 Incyte Recent Developments
6.7 Erasca
6.7.1 Erasca Comapny Information
6.7.2 Erasca Business Overview
6.7.3 Erasca KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Erasca KRAS Inhibitor Product Portfolio
6.7.5 Erasca Recent Developments
6.8 Cardiff Oncology
6.8.1 Cardiff Oncology Comapny Information
6.8.2 Cardiff Oncology Business Overview
6.8.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Cardiff Oncology KRAS Inhibitor Product Portfolio
6.8.5 Cardiff Oncology Recent Developments
6.9 BridgeBio Pharma
6.9.1 BridgeBio Pharma Comapny Information
6.9.2 BridgeBio Pharma Business Overview
6.9.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 BridgeBio Pharma KRAS Inhibitor Product Portfolio
6.9.5 BridgeBio Pharma Recent Developments
6.10 Boehringer Ingelheim
6.10.1 Boehringer Ingelheim Comapny Information
6.10.2 Boehringer Ingelheim Business Overview
6.10.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Boehringer Ingelheim KRAS Inhibitor Product Portfolio
6.10.5 Boehringer Ingelheim Recent Developments
7 North America by Country

7.1 North America KRAS Inhibitor Sales by Country
7.1.1 North America KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America KRAS Inhibitor Sales by Country (2020-2025)
7.1.3 North America KRAS Inhibitor Sales Forecast by Country (2026-2031)
7.2 North America KRAS Inhibitor Market Size by Country
7.2.1 North America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America KRAS Inhibitor Market Size by Country (2020-2025)
7.2.3 North America KRAS Inhibitor Market Size Forecast by Country (2026-2031)
8 Europe by Country

8.1 Europe KRAS Inhibitor Sales by Country
8.1.1 Europe KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe KRAS Inhibitor Sales by Country (2020-2025)
8.1.3 Europe KRAS Inhibitor Sales Forecast by Country (2026-2031)
8.2 Europe KRAS Inhibitor Market Size by Country
8.2.1 Europe KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe KRAS Inhibitor Market Size by Country (2020-2025)
8.2.3 Europe KRAS Inhibitor Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country

9.1 Asia-Pacific KRAS Inhibitor Sales by Country
9.1.1 Asia-Pacific KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific KRAS Inhibitor Sales by Country (2020-2025)
9.1.3 Asia-Pacific KRAS Inhibitor Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific KRAS Inhibitor Market Size by Country
9.2.1 Asia-Pacific KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific KRAS Inhibitor Market Size by Country (2020-2025)
9.2.3 Asia-Pacific KRAS Inhibitor Market Size Forecast by Country (2026-2031)
10 South America by Country

10.1 South America KRAS Inhibitor Sales by Country
10.1.1 South America KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America KRAS Inhibitor Sales by Country (2020-2025)
10.1.3 South America KRAS Inhibitor Sales Forecast by Country (2026-2031)
10.2 South America KRAS Inhibitor Market Size by Country
10.2.1 South America KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America KRAS Inhibitor Market Size by Country (2020-2025)
10.2.3 South America KRAS Inhibitor Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country

11.1 Middle East and Africa KRAS Inhibitor Sales by Country
11.1.1 Middle East and Africa KRAS Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa KRAS Inhibitor Sales by Country (2020-2025)
11.1.3 Middle East and Africa KRAS Inhibitor Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa KRAS Inhibitor Market Size by Country
11.2.1 Middle East and Africa KRAS Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa KRAS Inhibitor Market Size by Country (2020-2025)
11.2.3 Middle East and Africa KRAS Inhibitor Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis

12.1 KRAS Inhibitor Value Chain Analysis
12.1.1 KRAS Inhibitor Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 KRAS Inhibitor Production Mode & Process
12.2 KRAS Inhibitor Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 KRAS Inhibitor Distributors
12.2.3 KRAS Inhibitor Customers
13 Concluding Insights
14 Appendix

14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings